Evaluation of Circulating Tumor DNA Analysis and Biomarker Associations for Recurrence Risk After Curative Treatment of Resectable Solid Tumors

Evaluation of Circulating Tumor DNA Analysis and Biomarker Associations for Recurrence Risk After Curative Treatment of Resectable Solid Tumors - NeXT M3 Personal

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061075

Enrollment

330

Registered

2026-03-30

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer/Ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with colorectal cancer and ovarian cancer who were enrolled in the MONSTAR-SCREEN-3 trial (Cohort B) and received curative treatment

Exclusion criteria

Exclusion criteria: Cases with missing data required for this study. Cases deemed inappropriate for enrollment in this study by the principal investigator. Cases of withdrawal of consent or refusal of secondary use of specimens and/or data.

Design outcomes

Primary

Measure	Time frame
The association between ctDNA MRD and recurrence	—

Secondary

Measure	Time frame
Association between ctDNA and the efficacy of adjuvant therapy Association between ctDNA and efficacy of adjuvant therapy Overall survival (OS) ctDNA positivity rate Association between ctDNA and clinicopathological/molecular characteristics, etc.	—

Countries

Japan

Contacts

Public ContactTadayoshi Hashimoto

National Cancer Center Hospital East Division for the Promotion of Drug and Diagnostic Development

tadhashi@east.ncc.go.jp04-7133-1111

Outcome results